Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

BOUT
Sort by: Date|Relevance

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...
Knox Henderson | December 23, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Hydrogen stocks with top news; Plug, Nucera and DynaCERT in focus

Despite negative quarterly figures, the Plug Power stock has developed positively in recent days. Is this the turnaround for the hydrogen pure play? The Americans recently reported progress on a mega-project. DynaCERT is strengthening its position with an industry ex...
Fabian Lorenz | May 22, 2024 |

BioNTech & Cardiol Therapeutics – on the verge of a breakout

Compared with the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition t...
Stefan Feulner | May 22, 2024 |

It’s Time to Start Talking about the Elephant in the Room

By Jonathan Goodman We at Dundee Goodman Merchant Partners have spent most of our working lives in the resource industry. Collectively we are money managers, geologists, engineers, mining operators, and natural resource/mining bankers. Moreover, all of us are person...
Research | April 5, 2023 |

The Gold Play That’s Poised for a Breakout 2022

With the spot price of gold hovering around USD$2000 and inflation soaring, savvy metals & mining investors are looking for real value and opportunity in the precious metals exploration space. And, it’s gold that has historically provided the most proven tra...
Dave Jackson | April 27, 2022 |

Earning into 3 Exciting Opportunities. Who, What, Where, When & Why?

Looking for a value play in a well-structured mining exploration and development company? Well, Tocvan Ventures Corp. (TOC) ( CSE.TOC , OTCQB: TCVNF , Forum ) may be the kind of investment opportunity that is worth delving deeper into. TOC is currently e...
Dave Jackson | March 23, 2022 |

Siyata Mobile Still Bullish After Q2 Earnings Call

Earnings reports are useful for measuring financial milestones, but they don’t tell the whole story. Siyata Mobile (NASDAQ: SYTA, SYTAW) released their Q2 earnings on an October 15th call that included CEO Marc Seelenfreund, VP of Corporate Development Daniel...
Featured Submission | October 27, 2021 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

XPhyto Therapeutics: Are they Selling the Solution to Germany’s Rapid Testing Crisis?

The Germans call it COVID-19 “rapid testing mania”. But like most manias, it has opened up a Pandora’s box of problems. As the speed of the vaccine rollout program falters in Europe, on-the-spot antigen testing continues to be the ...
Marc Davis | June 2, 2021 |
1 2 3 4 5 6 7 8 9 10 ...